Theriva Biologics Statistics
Total Valuation
TOVX has a market cap or net worth of $3.52 million. The enterprise value is -$3.64 million.
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025, before market open.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TOVX has 8.19 million shares outstanding. The number of shares has increased by 181.75% in one year.
| Current Share Class | 8.19M |
| Shares Outstanding | 8.19M |
| Shares Change (YoY) | +181.75% |
| Shares Change (QoQ) | -0.37% |
| Owned by Insiders (%) | 0.16% |
| Owned by Institutions (%) | 6.96% |
| Float | 8.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.08 |
| P/TBV Ratio | 0.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.18.
| Current Ratio | 1.53 |
| Quick Ratio | 1.44 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -100.01% and return on invested capital (ROIC) is -41.14%.
| Return on Equity (ROE) | -100.01% |
| Return on Assets (ROA) | -27.71% |
| Return on Invested Capital (ROIC) | -41.14% |
| Return on Capital Employed (ROCE) | -74.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.13M |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.75% in the last 52 weeks. The beta is 0.83, so TOVX's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | -92.75% |
| 50-Day Moving Average | 0.74 |
| 200-Day Moving Average | 1.38 |
| Relative Strength Index (RSI) | 32.67 |
| Average Volume (20 Days) | 1,571,123 |
Short Selling Information
The latest short interest is 249,351, so 3.05% of the outstanding shares have been sold short.
| Short Interest | 249,351 |
| Short Previous Month | 172,674 |
| Short % of Shares Out | 3.05% |
| Short % of Float | 3.05% |
| Short Ratio (days to cover) | 0.16 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.93M |
| Pretax Income | -20.35M |
| Net Income | -24.81M |
| EBITDA | -17.81M |
| EBIT | -17.93M |
| Earnings Per Share (EPS) | -$13.25 |
Full Income StatementBalance Sheet
The company has $10.01 million in cash and $2.86 million in debt, giving a net cash position of $7.16 million or $0.87 per share.
| Cash & Cash Equivalents | 10.01M |
| Total Debt | 2.86M |
| Net Cash | 7.16M |
| Net Cash Per Share | $0.87 |
| Equity (Book Value) | 15.50M |
| Book Value Per Share | 5.57 |
| Working Capital | 4.33M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.81 million and capital expenditures -$1,000, giving a free cash flow of -$16.81 million.
| Operating Cash Flow | -16.81M |
| Capital Expenditures | -1,000 |
| Free Cash Flow | -16.81M |
| FCF Per Share | -$2.05 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
